Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Vladimir I. Vorobyev"'
Autor:
Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activi
Externí odkaz:
https://doaj.org/article/b83a79daf0fc4b7db69564adb35219aa
Autor:
Vera A. Zherebtsova, Vladimir I. Vorobyev, Eduard G. Gemdzhian, Margarita A. Ulyanova, Mikhail V. Chernikov, Valentina L. Ivanova, Olga Yu. Vinogradova, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 785-792 (2021)
Background. Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. Aim. Analysis of efficacy and safety of KRd in routine clinical
Externí odkaz:
https://doaj.org/article/85cd929c47ae441684465f6a1f7468ba
Autor:
Irina V. Poddubnaya, Elena A. Baryakh, Vladimir I. Vorobyev, E. A. Demina, Nikolay V. Zhukov, K. D. Kaplanov, T. S. Konstantinova, Dmitry V. Motorin, V. V. Ptushkin, Vladislav O. Sarzhevsky, G. S. Tumyan
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 52-55 (2020)
Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant patholog
Externí odkaz:
https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca
Autor:
Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Kamil D. Kaplanov, Andrei A. Petrenko, Oksana I. Ochirova, Alina Karpova, Ekaterina Yu. Chelysheva, Anna G. Turkina, Margarita A. Gurianova, Liubov S. Al-Radi, Elena A. Gilyazitdinova, Elena K. Egorova, Yulia A. Chabaeva, Sergey M. Kulikov, Yulia V. Sveshnikova, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika F. Rakhmani, Olga L. Panteleeva, Maria E. Grishunina, Olga S. Samoylova, Ekaterina Vorontsova, Daria V. Baryshnikova, Elena N. Parovichnikova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Autor:
Liudmila V. Fedorova, Elena V. Melnichenko, Kaplanov Kd, Elena V. Martynova, Vladimir I. Vorobyev, Natalia B. Mikhailova, Liliia P. Kaleikina, Natalia B. Bulieva, Olga S. Trubyakova, Elena P. Yakovleva, Elena P. Chumakova, Elena V. Tarasenko, Vadim V. Ptushkin, Olga Yu. Li, Lev S. Butaev, Ridvan K. Ilyasov, E S Nesterova, Vera A. Zherebtsova, Margolin Ov, Eduard G. Gemdzhian
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patien
Autor:
Vladimir I. Vorobyev, Anton Yu. Subora, Yulia A. Oleinik, Lev S. Butaev, Vera A. Zherebtsova, Darya G. Kisilichina, Margarita A. Ulyanova, Evdokiya S. Urnova, Alena M. Sukhareva, Matvei P. Bulusov
Publikováno v:
Blood. 140:7622-7623
Autor:
T S Konstantinova, Vladimir I. Vorobyev, Dmitry V. Motorin, Vladislav O. Sarzhevsky, Irina V. Poddubnaya, E A Baryakh, K. D. Kaplanov, Nikolay V. Zhukov, Vadim Ptushkin, Gayane Tumyan, E. A. Demina
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 52-55 (2020)
Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant patholog
Autor:
Meletios A. Dimopoulos, Cristina Gasparetto, Maeva Hellet, Pekka Anttila, Sandrine Macé, Marcelo Capra, Jian Y Yin, Matthew W Jenner, Eduardo Yanez Ruiz, Sara Bringhen, Vania Hungria, Vladimir I. Vorobyev, Rao Saleem, Craig E. Cole, Bruno Paiva, Michele Cavo, Ravi Vij
Publikováno v:
Blood
This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b155c38aec5b28a10a6674ed65d2f0f
http://hdl.handle.net/10138/334769
http://hdl.handle.net/10138/334769
Autor:
Sagar Lonial, Sebastian Grosicki, Marek Hus, Kevin W. Song, Thierry Facon, Natalie Scott Callander, Vincent Ribrag, Katarina Uttervall, Hang Quach, Vladimir I. Vorobyev, Chang Ki Min, Shinta Cheng, L. Mary Smith, Jing Yu, Therese Collingwood, Beata Holkova, Brandon Kremer, Ira Gupta, Paul G. Richardson, Monique C. Minnema
Publikováno v:
Journal of Clinical Oncology. 40:8019-8019
8019 Background: Preclinical data demonstrate that nirogacestat, a gamma-secretase inhibitor, may increase cell-surface levels of a B-cell maturation antigen (BCMA) and reduce soluble BCMA levels, which could enhance anti-BCMA agent activity in multi
Autor:
Valery G. Savchenko, Olga A. Gavrilina, Lubov Gavrilova, Gennadiy M. Galstyan, Alena Sukhareva, Alina Karpova, Ochsana Ochirova, Vasily Shuvaev, Anastasia N. Vasileva, Anton V. Luchkin, Olga Panteleeva, Kristina Zakurdaeva, Anzhelika F. Rakhmani, Mikhail A. Kunst, Tatiana V. Gaponova, Maria Grishunina, Olga Samoylova, Vera V. Troitskaya, Vladimir I. Vorobyev, Lev S. Butaev, Elena N. Parovichnikova
Publikováno v:
Blood
Background: Patients (pts) with hematologic disease are at increased risk of severe SARS-CoV-2 infection. Recent observations reported poor outcomes of COVID-19 in pts with various cancer types and higher mortality rates compared with the general pop